Based on the Iovance Biotherapeutics Inc stock forecast from 11 analysts, the average analyst target price for Iovance Biotherapeutics Inc is USD 11.66 over the next 12 months. Iovance Biotherapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Iovance Biotherapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Iovance Biotherapeutics Inc’s stock price was USD 2.31. Iovance Biotherapeutics Inc’s stock price has changed by +28.33% over the past week, +19.69% over the past month and -72.92% over the last year.
No recent analyst target price found for Iovance Biotherapeutics Inc
No recent average analyst rating found for Iovance Biotherapeutics Inc
Company Overview Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Read Less
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers A...Read More
Frequently Asked Questions About Iovance Biotherapeutics Inc (IOVA) Stock
Based on ratings from 11 analysts Iovance Biotherapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on IOVA's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for IOVA is USD 11.66 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on IOVA's stock to indicate if its overvalued.
The last closing price of IOVA's stock was USD 2.31.
The most recent market capitalization for IOVA is USD 0.55B.
Based on targets from 11 analysts, the average taret price for IOVA is projected at USD 11.66 over the next 12 months.
This means that IOVA's stock price may go up by +404.60% over the next 12 months.
We can't find any ETFs which contains Iovance Biotherapeutics Inc's stock.
As per our most recent records Iovance Biotherapeutics Inc has 838 Employees.
Iovance Biotherapeutics Inc's registered address is 825 Industrial Road, San Carlos, CA, United States, 94070.
You can get more information about it from Iovance Biotherapeutics Inc's website at https://www.iovance.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Iovance Biotherapeutics Inc (IOVA) Stock
Based on ratings from 11 analysts Iovance Biotherapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on IOVA's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for IOVA is USD 11.66 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on IOVA's stock to indicate if its overvalued.
The last closing price of IOVA's stock was USD 2.31.
The most recent market capitalization for IOVA is USD 0.55B.
Based on targets from 11 analysts, the average taret price for IOVA is projected at USD 11.66 over the next 12 months.
This means that IOVA's stock price may go up by +404.60% over the next 12 months.
We can't find any ETFs which contains Iovance Biotherapeutics Inc's stock.
As per our most recent records Iovance Biotherapeutics Inc has 838 Employees.
Iovance Biotherapeutics Inc's registered address is 825 Industrial Road, San Carlos, CA, United States, 94070.
You can get more information about it from Iovance Biotherapeutics Inc's website at https://www.iovance.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IOVA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
